Temodar and Csf test abnormal - a phase IV clinical study of FDA data
Summary:
We study 7,348 people who take Temodar (temozolomide) or have Csf test abnormal. No report of Csf test abnormal is found in people who take Temodar.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Temodar?
Temodar has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 6,683 Temodar users. Check the latest studies of Temodar.
What is Csf Test Abnormal?
Csf test abnormal is found to be associated with 106 drugs and 248 conditions by eHealthMe. Check the latest studies of Csf test abnormal.
No report is found.
Do you take Temodar and have Csf test abnormal?
- Check whether Csf test abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Temodar:
- Temodar (6,683 reports)
Csf test abnormal treatments and more:
- Csf test abnormal (665 reports)
How severe was Csf test abnormal and when was it recovered:
Expand to all the drugs that have ingredients of temozolomide:
Browse all side effects of Temodar:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Csf test abnormal:
Browse all the conditions that are associated with Csf test abnormal:
How the study uses the data?
The study uses data from the FDA. It is based on temozolomide (the active ingredients of Temodar) and Temodar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Silodosin cause Thrombocytopenia Aggravated? - 2 seconds ago
- Could Fluconazole cause Panic Disorder? - 2 seconds ago
- Could Zerit cause Weight Increased? - 2 seconds ago
- Could Oxycodone cause Immunodeficiency? - 6 seconds ago
- Escitalopram and Slurred Speech for Women aged 20-29 - 10 seconds ago
- Escitalopram and Language Impairment for Women aged 20-29 - 10 seconds ago
- Escitalopram and Inability To Speak for Women aged 20-29 - 10 seconds ago
- Escitalopram and Impairment Of Speech for Women aged 20-29 - 11 seconds ago
- Escitalopram and Dysphasia for Women aged 20-29 - 11 seconds ago
- Escitalopram and Dysarthria for Women aged 20-29 - 11 seconds ago